Global Sepsis Diagnostics Market 2022-2032

1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Fact.MR Analysis and Recommendations

2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations

3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Sepsis Diagnostics Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Componentulation and Product Development Trends

4.1. Sepsis Diagnostics Market By Country, US$ Mn
4.2. Sepsis Diagnostics Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Sepsis Diagnostics Market Growth
4.5.3. Sepsis Diagnostics Adoption Rate, by Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Sepsis Diagnostics Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking

6.1. Historical Market Analysis, 2015-2021
6.2. Current and Future Market Projections, 2022-2032
6.3. Y-o-Y Growth Trend Analysis

7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8.1. Introduction/Key Findings
8.2. Historical Market Value (US$ Mn) and Analysis By Product, 2015-2021
8.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Product, 2022-2032
8.3.1. Blood Culture Media
8.3.2. Assays & Reagents
8.3.3. Instruments
8.3.4. Software
8.4. Market Attractiveness Analysis By Product

9.1. Introduction/Key Findings
9.2. Historical Market Value (US$ Mn) and Analysis By Technology, 2015-2021
9.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Technology, 2022-2032
9.3.1. Blood Culture
9.3.2. Immunoassays
9.3.3. Molecular Diagnostics
9.3.3.1. PCR
9.3.3.2. Peptide Nucleic Acid-Fluorescent In Situ Hybridization
9.3.3.3. Microarrays
9.3.3.4. DNA Sequencing
9.3.3.5. Syndromic Panel-Based Testing
9.3.4. Flow Cytometry
9.3.5. Microfluidics
9.3.6. Biomarkers
9.4. Market Attractiveness Analysis By Technology

10.1.1. 10.1.Introduction/Key Findings
10.1.2. 10.2.Historical Market Value (US$ Mn) and Analysis By Method, 2015-2021
10.1.3. 10.3.Current and Future Market Value (US$ Mn) and Analysis and Forecast By Method, 2022-2032
10.1.3.1. 10.3.1. Automated Diagnostics
10.1.3.2. 10.3.2. Conventional Diagnostics
10.1.4. 10.4.Market Attractiveness Analysis By Method

11.1.1. 11.1.Introduction/Key Findings
11.1.2. 11.2.Historical Market Value (US$ Mn) and Analysis By Pathogen, 2015-2021
11.1.3. 11.3.Current and Future Market Value (US$ Mn) and Analysis and Forecast By Pathogen, 2022-2032
11.1.3.1. 11.3.1. Bacterial Sepsis
11.1.3.2. 11.3.2. Fungal Sepsis
11.1.3.3. 11.3.3. Viral Sepsis
11.1.3.4. 11.3.4. Other Pathogen
11.1.4. 11.4.Market Attractiveness Analysis By Pathogen

12.1.1. 12.1.Introduction/Key Findings
12.1.2. 12.2.Historical Market Value (US$ Mn) and Analysis By Test Type, 2015-2021
12.1.3. 12.3.Current and Future Market Value (US$ Mn) and Analysis and Forecast By Test Type, 2022-2032
12.1.3.1. 12.3.1. Laboratory Tests
12.1.3.2. 12.3.2. Point-of-Care Tests
12.1.4. 12.4.Market Attractiveness Analysis By Test Type

13.1. Introduction
13.2. Historical Market Value (US$ Mn) and Analysis By Region, 2015-2021
13.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032
13.3.1. Hospitals and Specialty Clinics
13.3.2. Pathology & Reference Laboratories
13.3.3. Research Laboratories & Academic Institutes
13.4. Market Attractiveness Analysis By Region

14.1. Introduction
14.2. Historical Market Value (US$ Mn) and Analysis By Region, 2015-2021
14.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. Asia Pacific
14.3.5. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region

15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
15.3.1.1. 15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country
15.3.1.1.1. 15.4.1.1. U.S.
15.3.1.1.2. 15.4.1.2. Canada
15.3.1.2. 15.4.2. By Method
15.3.1.3. 15.4.3. By Product
15.3.1.4. 15.4.4. By Technology
15.3.1.5. 15.4.5. By Pathogen
15.3.1.6. 15.4.6. By Test Type
15.3.1.7. 15.4.7. By End-User
15.4. Market Attractiveness Analysis
15.4.1.1. 15.5.1. By Country
15.4.1.2. 15.5.2. By Method
15.4.1.3. 15.5.3. By Product
15.4.1.4. 15.5.4. By Technology
15.4.1.5. 15.5.5. By Pathogen
15.4.1.6. 15.5.6. By Test Type
15.4.1.7. 15.5.7. By End-User

16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
16.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. Brazil
16.4.1.2. Mexico
16.4.1.3. Rest of Latin America
16.4.2. By Method
16.4.3. By Product
16.4.4. By Technology
16.4.5. By Pathogen
16.4.6. By Test Type
16.4.7. By End-User
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Method
16.5.3. By Product
16.5.4. By Technology
16.5.5. By Pathogen
16.5.6. By Test Type
16.5.7. By End-User

17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
17.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
17.4.1. By Country
17.4.1.1. Germany
17.4.1.2. France
17.4.1.3. U.K.
17.4.1.4. Italy
17.4.1.5. Benelux
17.4.1.6. Russia
17.4.1.7. Rest of Europe
17.4.2. By Method
17.4.3. By Product
17.4.4. By Technology
17.4.5. By Pathogen
17.4.6. By Test Type
17.4.7. By End-User
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Method
17.5.3. By Product
17.5.4. By Technology
17.5.5. By Pathogen
17.5.6. By Test Type
17.5.7. By End-User

18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
18.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
18.4.1. By Country
18.4.1.1. China
18.4.1.2. Japan
18.4.1.3. South Korea
18.4.1.4. Rest of Asia Pacific
18.4.2. By Method
18.4.3. By Product
18.4.4. By Technology
18.4.5. By Pathogen
18.4.6. By Test Type
18.4.7. By End-User
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Method
18.5.3. By Product
18.5.4. By Technology
18.5.5. By Pathogen
18.5.6. By Test Type
18.5.7. By End-User

19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
19.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. South Africa
19.4.1.3. Turkey
19.4.1.4. Rest of Middle East and Africa
19.4.2. By Method
19.4.3. By Product
19.4.4. By Technology
19.4.5. By Pathogen
19.4.6. By Test Type
19.4.7. By End-User
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Method
19.5.3. By Product
19.5.4. By Technology
19.5.5. By Pathogen
19.5.6. By Test Type
19.5.7. By End-User

20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. US Sepsis Diagnostics Market Analysis
20.2.1. Value Proportion Analysis by Market Taxonomy
20.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.2.2.1. By Method
20.2.2.2. By Product
20.2.2.3. By Technology
20.2.2.4. By Pathogen
20.2.2.5. By Test Type
20.2.2.6. By End-User
20.3. Canada Sepsis Diagnostics Market Analysis
20.3.1. Value Proportion Analysis by Market Taxonomy
20.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.3.2.1. By Method
20.3.2.2. By Product
20.3.2.3. By Technology
20.3.2.4. By Pathogen
20.3.2.5. By Test Type
20.3.2.6. By End-User
20.4. Mexico Sepsis Diagnostics Market Analysis
20.4.1. Value Proportion Analysis by Market Taxonomy
20.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.4.2.1. By Method
20.4.2.2. By Product
20.4.2.3. By Technology
20.4.2.4. By Pathogen
20.4.2.5. By Test Type
20.4.2.6. By End-User
20.5. Brazil Sepsis Diagnostics Market Analysis
20.5.1. Value Proportion Analysis by Market Taxonomy
20.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.5.2.1. By Method
20.5.2.2. By Product
20.5.2.3. By Technology
20.5.2.4. By Pathogen
20.5.2.5. By Test Type
20.5.2.6. By End-User
20.6. Germany Sepsis Diagnostics Market Analysis
20.6.1. Value Proportion Analysis by Market Taxonomy
20.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.6.2.1. By Method
20.6.2.2. By Product
20.6.2.3. By Technology
20.6.2.4. By Pathogen
20.6.2.5. By Test Type
20.6.2.6. By End-User
20.7. France Sepsis Diagnostics Market Analysis
20.7.1. Value Proportion Analysis by Market Taxonomy
20.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.7.2.1. By Method
20.7.2.2. By Product
20.7.2.3. By Technology
20.7.2.4. By Pathogen
20.7.2.5. By Test Type
20.7.2.6. By End-User
20.8. Italy Sepsis Diagnostics Market Analysis
20.8.1. Value Proportion Analysis by Market Taxonomy
20.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.8.2.1. By Method
20.8.2.2. By Product
20.8.2.3. By Technology
20.8.2.4. By Pathogen
20.8.2.5. By Test Type
20.8.2.6. By End-User
20.9. Russia Sepsis Diagnostics Market Analysis
20.9.1. Value Proportion Analysis by Market Taxonomy
20.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.9.2.1. By Method
20.9.2.2. By Product
20.9.2.3. By Technology
20.9.2.4. By Pathogen
20.9.2.5. By Test Type
20.9.2.6. By End-User
20.10. UK Sepsis Diagnostics Market Analysis
20.10.1. Value Proportion Analysis by Market Taxonomy
20.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.10.2.1. By Method
20.10.2.2. By Product
20.10.2.3. By Technology
20.10.2.4. By Pathogen
20.10.2.5. By Test Type
20.10.2.6. By End-User
20.11. Benelux Sepsis Diagnostics Market Analysis
20.11.1. Value Proportion Analysis by Market Taxonomy
20.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.11.2.1. By Method
20.11.2.2. By Product
20.11.2.3. By Technology
20.11.2.4. By Pathogen
20.11.2.5. By Test Type
20.11.2.6. By End-User
20.12. China Sepsis Diagnostics Market Analysis
20.12.1. Value Proportion Analysis by Market Taxonomy
20.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.12.2.1. By Method
20.12.2.2. By Product
20.12.2.3. By Technology
20.12.2.4. By Pathogen
20.12.2.5. By Test Type
20.12.2.6. By End-User
20.13. Japan Sepsis Diagnostics Market Analysis
20.13.1. Value Proportion Analysis by Market Taxonomy
20.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.13.2.1. By Method
20.13.2.2. By Product
20.13.2.3. By Technology
20.13.2.4. By Pathogen
20.13.2.5. By Test Type
20.13.2.6. By End-User
20.14. South Korea Sepsis Diagnostics Market Analysis
20.14.1. Value Proportion Analysis by Market Taxonomy
20.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.14.2.1. By Method
20.14.2.2. By Product
20.14.2.3. By Technology
20.14.2.4. By Pathogen
20.14.2.5. By Test Type
20.14.2.6. By End-User
20.15. GCC Countries Sepsis Diagnostics Market Analysis
20.15.1. Value Proportion Analysis by Market Taxonomy
20.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.15.2.1. By Method
20.15.2.2. By Product
20.15.2.3. By Technology
20.15.2.4. By Pathogen
20.15.2.5. By Test Type
20.15.2.6. By End-User
20.16. South Africa Sepsis Diagnostics Market Analysis
20.16.1. Value Proportion Analysis by Market Taxonomy
20.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.16.2.1. By Method
20.16.2.2. By Product
20.16.2.3. By Technology
20.16.2.4. By Pathogen
20.16.2.5. By Test Type
20.16.2.6. By End-User
20.17. Turkey Sepsis Diagnostics Market Analysis
20.17.1. Value Proportion Analysis by Market Taxonomy
20.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
20.17.2.1. By Method
20.17.2.2. By Product
20.17.2.3. By Technology
20.17.2.4. By Pathogen
20.17.2.5. By Test Type
20.17.2.6. By End-User
20.17.3. Competition Landscape and Player Concentration in the Country

21.1. Market Analysis by Tier of Companies
21.2. Market Concentration
21.3. Market Share Analysis of Top Players
21.4. Market Presence Analysis
21.4.1. By Regional footprint of Players
21.4.2. Product footprint by Players

22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. BIOMÉRIEUX
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Sales Footprint
22.3.1.4. Strategy Overview
22.3.2. BECTON, DICKINSON, AND COMPANY
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Sales Footprint
22.3.2.4. Strategy Overview
22.3.3. DANAHER CORPORATION
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Sales Footprint
22.3.3.4. Strategy Overview
22.3.4. T2 BIOSYSTEMS
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Sales Footprint
22.3.4.4. Strategy Overview
22.3.5. LUMINEX
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Sales Footprint
22.3.5.4. Strategy Overview
22.3.6. F. HOFFMANN-LA ROCHE AG
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Sales Footprint
22.3.6.4. Strategy Overview
22.3.7. THERMO FISHER SCIENTIFIC
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Sales Footprint
22.3.7.4. Strategy Overview
22.3.8. BRUKER CORPORATION
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Sales Footprint
22.3.8.4. Strategy Overview
22.3.9. ABBOTT LABORATORIES
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Sales Footprint
22.3.9.4. Strategy Overview
22.3.10. QUIDEL CORPORATION
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Sales Footprint
22.3.10.4. Strategy Overview